1,4-Dioxacyclodotriaconta-17,19-diyne-5,32-dione, 2-(hydroxymethyl)-,(S)- (139100-90-6)

Identification
Name:	1,4-Dioxacyclodotriaconta-17,19-diyne-5,32-dione, 2-(hydroxymethyl)-,(S)-
CAS:	139100-90-6
Molecular Formula:	C₃₁H₅₀O₅
Molecular Structure:
Properties
Safety Data

Other Product

1,4-Dioxacyclodotriaconta-17,19-diyne-5,32-dione,2-[[(4-methoxyphenyl)methoxy]methyl]-, (S)-
1/C27H27N3O3S/c1-30-25(20-11-15-23(33-3)16-12-20)24(19-9-13-22(32-2)14-10-19)29-27(30)34-18-17-28-26(31)21-7-5-4-6-8-21/h4-16H,17-18H2,1-3H3,(H,28,31
17-Hydroxy-1-methyl-19-norpregn-4-ene-3,20-dione
19-Norpregn-4-ene-3,20-dione,17-[(1-oxohexyl)oxy]-
1/C51H74N2/c1-5-9-13-17-21-49(22-18-14-10-6-2)42-53(43-50(23-19-15-11-7-3)24-20-16-12-8-4)51-39-37-47(38-40-51)32-31-45-27-25-44(26-28-45)29-30-46-33-35-48(41-52)36-34-46/h25-40,49-50H,5-24,42-43H2,1-4H3/b30-29+,32-31
1/C33H42O7/c1-19-25-17-24-18-27(39-22(4)35)20(2)29(32(24,5)6)30(37)31(33(25,7)16-15-26(19)38-21(3)34)40-28(36)14-13-23-11-9-8-10-12-23/h8-14,24-27,30-31,37H,1,15-18H2,2-7H3/b14-13+/t24-,25-,26+,27+,30-,31+,33-/m1/s
1/C28H41N5O15S.Na/c1-12(2)21(28(42)43)33-26(41)17(9-15-5-7-16(8-6-15)48-49(44,45)46)31-25(40)18(29-13(3)35)10-20(37)32-27-22(30-14(4)36)24(39)23(38)19(11-34)47-27;/h5-8,12,17-19,21-24,27,34,38-39H,9-11H2,1-4H3,(H,29,35)(H,30,36)(H,31,40)(H,32,37)(H,33,41
19-Norpregn-4-ene-3,20-dione,17-hydroxy-
19-Norpregn-4-ene-3,20-dione,17-hydroxy-, (17a)-(9CI)
19-Norpregn-4-ene-3,20-dione,17-(acetyloxy)-
(4S,8R,10R)-4-(hydroxymethyl)-4,8,10,13-tetramethyl-17-[(3R)-5-(2-methylprop-1-enyl)tetrahydrofuran-3-yl]-6,9,11,12,16,17-hexahydro-5H-cyclopenta[a]phenanthrene-3,7-dione
4-Octene-2,6-diyne-1,8-dione,1,8-di-2-thienyl-
Androst-4-en-3-one,17-hydroxy-,(17â)-,mixt. with 3,7-dihydro-7-(2-hydroxyethyl)-1,- 3-dimethyl-1H-purine-2,6-dione,3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6- dione,(17â)-10-ethyl-17-hydroxyestr-4-en- 3-one,4-hydroxy-R-[1-[(1-methyl-3-phenylpropyl) amino]ethyl]benzenemethanol hydrochloride and (17R)-19-norpregna-1,3,5(10)-trien-20-yne- 3,17-diol
Androst-4-en-3-one,17-hydroxy-,(17â)-,mixt. with 3,7-dihydro-7-(2-hydroxyethyl)-1,- 3-dimethyl-1H-purine-2,6-dione,3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6- dione,(17â)-10-ethyl-17-hydroxyestr-4-en- 3-one,4-hydroxy-R-[1-[(1-methyl-3-phenylpropyl) amino]ethyl]benzenemethanol hydrochloride and (17R)-19-norpregna-1,3,5(10)-trien-20-yne- 3,17-diol
17--(1-METHALLYL)-19-NORTESTOSTERONE
Spiro[cyclopentane-1,2'-[9,4](epoxypentadeca[1,11,13]trienimino)[2H]furo[2',3':7,8]naphth[1,2-d]imidazole]-10',26'(9'H)-dione,16'-(acetyloxy)-1',3'-dihydro-5',6',18',20'-tetrahydroxy-14'-methoxy-7',9',15',17',19',21',25'-heptamethyl-,[9'S-(9'R*,12'E,14'R*,15'S*,16'R*,17'S*,18'S*,19'S*,20'R*,21'R*,22'E,24'Z)]-(9CI)
Spiro[cyclohexane-1,2'-[9,4](epoxypentadeca[1,11,- 13]trienimino)[2H]furo[2',3':7,8]naphth[1,2-d]- imidazole]-10',26'(9'H)-dione,16'-(acetyloxy)- 1',3'-dihydro-5',6',18',20'-tetrahydroxy-14'- methoxy-7',9',15',17',19',21',25'-heptamethyl-,(9'S,12'E,14'S,15'R,16'S,17'R,18'R,19'R,20'S,- 21'S,22'E,24'Z)-
1/C14H9Br2O2P/c15-11-6-8-13(17-11)19(10-4-2-1-3-5-10)14-9-7-12(16)18-14/h1-9
1/C15H10O4/c16-11-7-3-1-5-9(11)15-14(18)13(17)10-6-2-4-8-12(10)19-15/h1-8,16,18
1/C11H14N2O6/c1-17-7(14)4-12-2-3-13-9(10(12)15)8-6(19-13)5-18-11(8)16/h6,8-9H,2-5H2,1H